Clinical Uses of rHuEpo for Prevention of Anemia
| Use . | Subjects Most Likely to Benefit From Treatment . | Optimal Treatment Schedule . |
|---|---|---|
| 1. Autologous blood donation before surgery | Anemic patients (Hb <13.5 g/dL or Hct <40%), subjects with a calculated blood volume <5 L and expected blood loss ≥4 U, and alloimmunized patients. Treatment may also be justified in patients who reject transfusions because of religious conviction and in bone marrow donors. | 250-300 IU/kg rHuEpo SC twice weekly over the 3-week period before surgery. IV iron supplementation (iron saccharate at 200 mg) is administered at each donation visit. Alternatively, at least 200 mg of oral elemental iron should be administered daily (see also Fig 5). |
| 2. Perioperative adjunctive therapy | Surgical patients who are excluded from autologous blood programs because of a time to surgery <3 weeks or for logistical reasons. | See Fig 5. Normovolemic hemodilution should be considered in combination. |
| 3. Prevention of anemia and transfusion requirement in patients undergoing platinum-based combination chemotherapy | Patients undergoing platinum-based combination chemotherapy (with doses prone to induce anemia: cisplatin at 75 mg/m2/cycle or more; carboplatin at 350 mg/m2/cycle or more) and showing borderline or low Hb levels. | 150 IU/kg rHuEpo SC three times weekly during the whole chemotherapy treatment. |
| Use . | Subjects Most Likely to Benefit From Treatment . | Optimal Treatment Schedule . |
|---|---|---|
| 1. Autologous blood donation before surgery | Anemic patients (Hb <13.5 g/dL or Hct <40%), subjects with a calculated blood volume <5 L and expected blood loss ≥4 U, and alloimmunized patients. Treatment may also be justified in patients who reject transfusions because of religious conviction and in bone marrow donors. | 250-300 IU/kg rHuEpo SC twice weekly over the 3-week period before surgery. IV iron supplementation (iron saccharate at 200 mg) is administered at each donation visit. Alternatively, at least 200 mg of oral elemental iron should be administered daily (see also Fig 5). |
| 2. Perioperative adjunctive therapy | Surgical patients who are excluded from autologous blood programs because of a time to surgery <3 weeks or for logistical reasons. | See Fig 5. Normovolemic hemodilution should be considered in combination. |
| 3. Prevention of anemia and transfusion requirement in patients undergoing platinum-based combination chemotherapy | Patients undergoing platinum-based combination chemotherapy (with doses prone to induce anemia: cisplatin at 75 mg/m2/cycle or more; carboplatin at 350 mg/m2/cycle or more) and showing borderline or low Hb levels. | 150 IU/kg rHuEpo SC three times weekly during the whole chemotherapy treatment. |